Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition.
Weintraub Y., Collen LV., Hussey S., Mitrova K., Machta JS., Kang B., Granot M., D'Arcangelo G., Spencer EA., Kolho K-L., Yeh P-J., Sladek M., Scarallo L., Palomino L., Afzal NA., de Laffolie J., Miele E., Bramuzzo M., Olén O., Russell RK., Rohani P., Tzivinikos C., Urlep D., van Rheenen PF., de Ridder L., Yogev D., Schneider A-M., Cohen S., Garcia-Romero R., Dipasquale V., Uhlig HH., Shouval DS.
BACKGROUND AND AIMS: Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset